Bailard’s Five Prime Therapeutics FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-22,000
Closed -$829K – 779
2021
Q1
$829K Buy
+22,000
New +$549K 0.03% 284
2019
Q4
– Sell
-13,000
Closed -$50K – 627
2019
Q3
$50K Hold
13,000
– – ﹤0.01% 528
2019
Q2
$78K Buy
13,000
+2,500
+24% +$23.9K ﹤0.01% 533
2019
Q1
$141K Buy
+10,500
New +$120K 0.01% 518

Bailard's FPRX Position: Q2 2021 in Review

Bailard sold out of Five Prime Therapeutics (FPRX) in Q2 2021, closing a stake of 22,000 shares — an estimated $829K sold.

Bailard first reported a position in FPRX in Q1 2019 and held it in 4 quarters. The position peaked at $829K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Bailard reported no remaining Five Prime Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bailard sold 22,000 Five Prime Therapeutics shares in Q2 2021, an estimated $829K.
  • Bailard first reported a position in Five Prime Therapeutics in Q1 2019 and held it in 4 quarters.
  • Bailard's Five Prime Therapeutics position peaked at $829K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics as of Q2 2021.

Based on Bailard's 13F filing for Q2 2021, filed 13 Aug 2021.